Owens & Minor: preliminary Q4 net loss ~$300M, $310M goodwill impairment; launches financing for Rotech acquisition

ACCENDRA HEALTH INC/VA/

2024-FY EPS reported -$4.73 revenue$10,700,883,000

Q4 prelim rev $2.67-2.70B; net loss $(288-311)M; adj EBITDA $135-140M; adj EPS $0.52-0.55.
FY2024 prelim rev $10.67-10.70B; net loss $(355-378)M; adj EBITDA $520-525M; adj EPS $1.50-1.53.
Non-cash goodwill impairment ~$310M in Apria division from stock decline, rates, contract pricing.
Total debt reduced by over $240M in 2024; total debt ~$1.854-1.859B; net debt ~$1.805-1.810B.
Commenced financing for previously announced Rotech acquisition; expected close 1H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.